Companies · Biotechnology
CLEVELAND · Biotechnology
Diligence memoA one-page analyst read on Athersys, Inc / New — recommendation, valuation, rhythm, risks.→Athersys, Inc / New looks fair against its niche peers and is at-risk on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Athersys, Inc / New is one of 4291 Biotechnology companies tracked from CLEVELAND. By capital raised it ranks mid-pack (ahead of 60% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 60% of sector peers (real $). Modeled value above 37% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #188 of 303.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| GeoVax Labs, Inc. | Series A | $39.1M | $217.0M | 4.90× |
| Cellinfinity Bio Holding Company, LLC | Series A | $13.2M | $215.9M | 4.87× |
| Adient Medical, Inc. | Series A | $18.2M | $206.8M | 4.67× |
| Entegrion Inc | Series A | $22.7M | $191.3M | 4.32× |
| BCD Bioscience, Inc. | Series A | $16.4M | $188.9M | 4.27× |
| Pragma Biosciences Inc. | Series A | $14.5M | $186.0M | 4.20× |
| MicroByre, Inc. | Series A | $16.1M | $185.7M | 4.19× |
| Cardiac Insight, Inc. | Series A | $38.1M | $183.8M | 4.15× |
| Cardiac Implants LLC | Series A | $13.5M | $178.2M | 4.02× |
| Abintus Bio, Inc. | Series A | $13.7M | $177.2M | 4.00× |
| Mosaic Biosciences, Inc. | Series A | $14.7M | $176.1M | 3.98× |
| Mazen Animal Health Inc. | Series A | $13.5M | $168.8M | 3.81× |
| Athersys, Inc / New this company | Series A | $12.5M | $33.2M | 0.75× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $9.0M | 2012-03-09 | $40.9M | $325.4M | 85% |
| Series A | $3.5M | 2023-04-18 | $16.1M | $33.2M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Joseph Nolan | — | 4 other | 2023-04 |
| Lorin J Randall | — | 2 other | 2012-03 |
| ISMAIL KOLA | — | 1 other | 2023-04 |
| DANIEL CAMARDO | — | — | 2023-04 |
| George M. Milne | — | — | 2012-03 |
| Gil Van Bokkelen | — | — | 2012-03 |
| Ismail E. Kola | — | — | 2012-03 |
| Jack L. Wyszomlerski | — | — | 2012-03 |
| JACK WYSZOMIERSKI | — | — | 2023-04 |
| JANE WASMAN | — | — | 2023-04 |
| John J. Harrington | — | — | 2012-03 |
| KASEY ROSADO | — | — | 2023-04 |
| Laura K. Campbell | — | — | 2012-03 |
| Lee E. Babiss | — | — | 2012-03 |
| MAIA HANSEN | — | — | 2023-04 |
| William L. Lehmann | — | — | 2012-03 |
Athersys, Inc / New is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Nanosphere Inc | Biotechnology | Series A | $4.1M | $147.1M | network1 shared operator · same sector · same stage |
| nference, inc. | Biotechnology | Series A | $12.3M | $32.6M | same sector · same stage |
| Digital Biotechnologies, Inc. | Biotechnology | Series A | $12.3M | $31.8M | same sector · same stage |
| Luna Genetics, Inc. | Biotechnology | Series A | $12.1M | $32.3M | same sector · same stage |
| Alida Biosciences Inc. | Biotechnology | Series A | $12.0M | $40.7M | same sector · same stage |
| Quellis Biosciences, Inc. | Biotechnology | Series A | $13.1M | $29.7M | same sector · same stage |
| Panome Bio Inc. | Biotechnology | Series A | $12.0M | $26.3M | same sector · same stage |
| Parcel Biosciences, Inc. | Biotechnology | Series A | $13.2M | $31.9M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Attralus, Inc. | Biotechnology | Series D+ | $708.5M | 84% |
| Atreca, Inc. | Biotechnology | Series D+ | $5.2B | 84% |
| Florey Biosciences, Inc. | Biotechnology | Seed | $4.4M | 83% |
| New Equilibrium Biosciences, Inc. | Biotechnology | Series A | $256.3M | 83% |
| Newomics Inc. | Biotechnology | Seed | $148.7M | 83% |
| Biotricity Inc. | Biotechnology | Series A | $6.0M | 83% |
| NewLimit, Inc. | Biotechnology | Series D+ | $1.1B | 83% |
| Peptilogics, Inc. | Biotechnology | Series B | $1.2B | 83% |
See where Athersys, Inc / New sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Athersys, Inc / New, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.